U.S. Stock Market Moves: Adaptive Shares Plunge on October 30 Due to Q3 Pre-loss, Stake Reduction, Competitor Progress, and High-Level Correction

Adaptive October 30 Major Drop Interpretation

Keywords: Q3 predicted loss, share reduction, competitor advances, high-level pullback

1. On November 4, the company will release its 2026 Q3 financial report after market close. Institutions predict revenue of $71.6009 million, down 23.81% year-on-year, and earnings per share of -$0.091, turning from profit to loss year-on-year.

2. On October 19, the company's President and Chief Operating Officer sold 35,643 shares, with a transaction amount of about $879,000. This was disclosed on October 22.

3. On October 29, Telo Genomics announced the expansion of its multi-center clinical study to compare its TELO-MRD with the company’s clonoSEQ for validation, involving competition in multiple myeloma MRD testing.

4. On October 26, the company closed at $26.92, up 61.36% cumulatively for the year, with a 52-week range of $12.00–$30.74; as of October 31, data showed a 2.72% increase in the past five days, within a high range.

(Disclaimer: This content is generated by AI technology summarizing public information and is for reference only. It does not constitute investment advice.)